![](https://endpts.com/wp-content/uploads/2021/02/Jeff-Hatfield-Vividion-tile-scaled.jpg)
Jeff Hatfield, Vividion CEO
‘Pluck those diamonds’: Bayer’s Vividion eyes up to nine oncology targets from Duke spinout
After snapping up Vividion before it could jump onto Nasdaq last August, Bayer’s preclinical ‘arms-length’ subsidiary is betting on a relatively unknown North Carolina upstart …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.